Crossmark Global Holdings Inc. Sells 3,253 Shares of Organon & Co. (NYSE:OGN)

Crossmark Global Holdings Inc. reduced its holdings in shares of Organon & Co. (NYSE:OGN) by 16.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,904 shares of the company’s stock after selling 3,253 shares during the period. Crossmark Global Holdings Inc.’s holdings in Organon & Co. were worth $252,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of OGN. Prospera Private Wealth LLC bought a new stake in shares of Organon & Co. during the third quarter valued at approximately $25,000. William B. Walkup & Associates Inc. purchased a new position in Organon & Co. during the second quarter valued at $31,000. Horizon Bancorp Inc. IN raised its stake in Organon & Co. by 2,401.5% during the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock valued at $25,000 after buying an additional 1,585 shares during the last quarter. Abich Financial Wealth Management LLC raised its stake in Organon & Co. by 5,646.3% during the third quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company’s stock valued at $45,000 after buying an additional 2,315 shares during the last quarter. Finally, Trust Co. of Vermont raised its stake in Organon & Co. by 109.4% during the third quarter. Trust Co. of Vermont now owns 2,626 shares of the company’s stock valued at $50,000 after buying an additional 1,372 shares during the last quarter. 77.43% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, TD Cowen upgraded Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $21.33.

Organon & Co. Price Performance

Organon & Co. stock opened at $16.26 on Tuesday. The firm has a 50-day moving average of $15.39 and a two-hundred day moving average of $18.03. Organon & Co. has a 1 year low of $13.87 and a 1 year high of $23.10. The stock has a market cap of $4.19 billion, a price-to-earnings ratio of 3.23, a price-to-earnings-growth ratio of 0.87 and a beta of 0.76. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.03). The firm had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.56 billion. Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The company’s revenue was up 4.1% compared to the same quarter last year. During the same quarter last year, the firm earned $0.78 EPS. On average, research analysts forecast that Organon & Co. will post 3.82 earnings per share for the current year.

Organon & Co. Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, December 12th. Investors of record on Tuesday, November 12th were issued a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 6.89%. The ex-dividend date was Tuesday, November 12th. Organon & Co.’s dividend payout ratio (DPR) is presently 22.22%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.